Back
Compare AU
Compare ETPMPT vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are ETPMPT and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
ETPMPT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 44 | 67 |
Median incremental investment | $1,997.50 | $665.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,767.50 | $1,882.88 |
Average age group | > 35 | > 35 |
Key Summary
ETPMPT | CURE | |
|---|---|---|
Strategy | ETPMPT.AX was created on 2009-01-02 by ETFS. The fund's investment portfolio concentrates primarily on platinum commodities. ETFS Physical Platinum (ETPMPT.AX) is designed to offer investors a simple, cost-efficient and secure way to access physical platinum by providing a return equivalent to the movements in the platinum spot price less the applicable management fee. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 40.41m in AUM and 144 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Global X Metal Securities Australia Limited (100 %) | Moderna Inc (2.14 %) Roivant Sciences Ltd Ordinary Shares (1.69 %) Vaxcyte Inc Ordinary Shares (1.66 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | |
Management fee | 0.49 % | 0.45 % |
Key Summary
ETPMPT | CURE | |
|---|---|---|
Issuer | ETFS | Global X |
Tracking index | LBMA Platinum Spot Price AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.49 % | 0.45 % |
Price | $276.75 | $58.84 |
Size | $103.313 million | $40.284 million |
10Y return | 114.53 % | N/A |
Annual dividend/ distribution yield (5Y) | - % | 5.08 % |
Market | ASX | ASX |
First listed date | 30/01/2009 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ETPMPT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 44 | 67 |
Median incremental investment | $1,997.50 | $665.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,767.50 | $1,882.88 |
Average age group | > 35 | > 35 |
Pros and Cons
ETPMPT | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ETPMPT | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |